Cancer Research and Treatment

Original Article

Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib: Jeong-Ju Yoo, Goh Eun Chung, Jeong-Hoon Lee, Joon Yeul Nam, Young Chang, Jeong Min Lee, Dong Ho Lee, Hwi Young Kim, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Seoul Liver Group; Cancer Res Treat. 2018;50(2):366-373. Published online May 15, 2017; DOI: https://doi.org/10.4143/crt.2017.126

Purpose
Advanced hepatocellular carcinoma (HCC) is associated with various clinical conditions including major vessel invasion, metastasis, and poor performance status. The aim of this study was to establish a prognostic scoring system and to propose a sub-classification of the Barcelona-Clinic Liver Cancer (BCLC) stage C.
Materials and Methods
This retrospective study included consecutive patientswho received sorafenib for BCLC stage C HCC at a single tertiary hospital in Korea. A Cox proportional hazard model was used to develop a scoring system, and internal validationwas performed by a 5-fold cross-validation. The performance of the model in predicting risk was assessed by the area under the curve and the Hosmer-Lemeshow test.
Results
A total of 612 BCLC stage C HCC patients were sub- classified into strata depending on their performance status. Five independent prognostic factors (Child-Pugh score, α-fetoprotein, tumor type, extrahepatic metastasis, and portal vein invasion) were identified and used in the prognostic scoring system. This scoring system showed good discrimination (area under the receiver operating characteristic curve, 0.734 to 0.818) and calibration functions (both p < 0.05 by the Hosmer-Lemeshow test at 1 month and 12 months, respectively). The differences in survival among the different risk groups classified by the total score were significant (p < 0.001 by the log-rank test in both the Eastern Cooperative Oncology Group 0 and 1 strata).
Conclusion
The heterogeneity of patientswith BCLC stage C HCC requires sub-classification of advanced HCC. A prognostic scoring system with five independent factors is useful in predicting the survival of patients with BCLC stage C HCC.

Citations

Citations to this article as recorded by

Tumor burden affects the progression pattern on the prognosis in patients treated with sorafenib
Jun Sun, Dongdong Xia, Wei Bai, Xiaomei Li, Enxing Wang, ZhanXin Yin, Guohong Han
Frontiers in Oncology.2024;[Epub] CrossRef
A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Ji W. Han, Soon K. Lee, Jung H. Kwon, Soon W. Nam, Hyun Yang, Si H. Bae, Ji H. Kim, Heechul Nam, Chang W. Kim, Hae L. Lee, Hee Y. Kim, Sung W. Lee, Ahlim Lee, U I. Chang, Do S. Song, Seok-Hwan Kim, Myeong J. Song, Pil S. Sung, Jong Y. Choi, Seung K. Yoon,
Clinical Cancer Research.2024; 30(13): 2812. CrossRef
Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment
Sujin Jin, Won-Mook Choi, Ju Hyun Shim, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jinhong Jung, Sang Min Yoon, Jonggi Choi
Journal of Liver Cancer.2023; 23(1): 177. CrossRef
Development and validation of web‐based prognostic nomograms for massive hepatocellular carcinoma (≥10 cm): A retrospective study based on the SEER database
Guizhong Huang, Qiaohong Lin, Pengfei Yin, Kai Mao, Jianlong Zhang
Cancer Medicine.2023; 12(12): 13167. CrossRef
Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma
Xiaomi Li, Xiaoyan Ding, Mei Liu, Jingyan Wang, Wei Li, Jinglong Chen
The Oncologist.2023; 28(10): e942. CrossRef
Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal
Li Li, Xiaomi Li, Wendong Li, Xiaoyan Ding, Yongchao Zhang, Jinglong Chen, Wei Li
BMC Cancer.2022;[Epub] CrossRef
Identification and validation of a prognostic model of necroptosis-related lncRNAs in hepatocellular carcinoma
Min Chen, Guang-Bo Wu, Shan Hua, Zhi-Feng Zhao, Hong-Jie Li, Meng Luo
Frontiers in Genetics.2022;[Epub] CrossRef
Prognostic value of a nomogram based on peripheral blood immune parameters in unresectable hepatocellular carcinoma after intensity-modulated radiotherapy
Jian-Xu Li, Mei-Ling He, Mo-Qin Qiu, Liu-Ying Yan, Mei-Ying Long, Jian-Hong Zhong, Rui-Jun Zhang, Chun-Feng Liang, Ya-Dan Pang, Jun-Kun He, Qian-Qian Chen, Jin-Xia Weng, Shi-Xiong Liang, Bang-De Xiang
BMC Gastroenterology.2022;[Epub] CrossRef
A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study
Giovanni Marasco, Francesco Poggioli, Antonio Colecchia, Giuseppe Cabibbo, Filippo Pelizzaro, Edoardo Giannini, Sara Marinelli, Gian Rapaccini, Eugenio Caturelli, Mariella Di Marco, Elisabetta Biasini, Fabio Marra, Filomena Morisco, Francesco Foschi, Marc
Cancers.2021; 13(11): 2677. CrossRef
Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study
Young Youn Cho, Su Jong Yu, Hye Won Lee, Do Young Kim, Wonseok Kang, Yong-Han Paik, Pil Soo Sung, Si Hyun Bae, Su Cheol Park, Young Seok Doh, Kang Mo Kim, Eun Sun Jang, In Hee Kim, Won Kim, Yoon Jun Kim
Journal of Hepatocellular Carcinoma.2021; Volume 8: 613. CrossRef
Identification and Validation of a Prognostic Prediction Model of m6A Regulator-Related LncRNAs in Hepatocellular Carcinoma
Chen Jin, Rui Li, Tuo Deng, Jialiang Li, Yan Yang, Haoqi Li, Kaiyu Chen, Huihua Xiong, Gang Chen, Yi Wang
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Construction and validation of an N6‑methyladenosine‑associated prognostic signature in hepatocellular carcinoma
Peng Zhu, Qianqian Ren, Nan He, Cheng Zhou, Qianna Jin, Zhao Gong
Oncology Letters.2021;[Epub] CrossRef
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
Tim A. Labeur, Sarah Berhane, Julien Edeline, Jean‐Frederic Blanc, Dominik Bettinger, Tim Meyer, Jeroen L. A. Van Vugt, David W. G. Ten Cate, Robert A. De Man, Ferry A. L. M. Eskens, Alessandro Cucchetti, Laura J. Bonnett, Otto M. Van Delden, Heinz‐Josef
Liver International.2020; 40(1): 215. CrossRef
A novel prognostic score model based on combining systemic and hepatic inflammation markers in the prognosis of HBV-associated hepatocellular carcinoma patients
Tingting Zhang, Zhe Liu, Xiangqian Zhao, Zhiyuan Mao, Li Bai
Artificial Cells, Nanomedicine, and Biotechnology.2019; 47(1): 2246. CrossRef
Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C
Yeon Joo Kim, Jinhong Jung, Ji Hyeon Joo, So Yeon Kim, Jin Hyoung Kim, Young-Suk Lim, Han Chu Lee, Jong Hoon Kim, Sang Min Yoon
Radiotherapy and Oncology.2019; 141: 95. CrossRef
Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation
Bo Hyun Kim, Joong-Won Park
Journal of Korean Medical Science.2018;[Epub] CrossRef

11,013 View
309 Download
18 Web of Science
16 Crossref

First
Prev
Page of 1
Next
Last

Search